All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Annie Im, University of Pittsburgh, Pittsburgh, US. We asked about itacitinib and corticosteroids for chronic graft-versus-host disease.
Itacitinib and corticosteroids for chronic GvHD
Im opens by discussing steroid treatment, which remains the standard of care, and the need for improved therapied based on disease outcomes. Im goes on to outline itacitinib, a JAK1 inhibitor, as a potential new treatment which could be used either alone or in combination with steroids. Im then discusses results from the GRAVITAS-309 trial, including the overall response and adverse events. Finally, Im summarizes the study conclusions on the future of combination treatments involving itacitinib and corticosteroids.
What is the latest update on the GRAVITAS-309 trial?
During the 64th American Society of Hematology Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, What is the latest...
ASH 2022 abstracts: What’s hot in GvHD?
To help navigate the exciting content being presented at ASH 2022, the GvHD Hub Steering Committee have provided their recommendations for the top abstracts to look out for in GvHD.
Subscribe to get the best content related to GvHD delivered to your inbox